Cargando…
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two gene...
Autores principales: | Pataer, Apar, Shao, Ruping, Correa, Arlene M., Behrens, Carmen, Roth, Jack A., Vaporciyan, Ara A., Wistuba, Ignacio I., Swisher, Stephen G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010873/ https://www.ncbi.nlm.nih.gov/pubmed/29673125 http://dx.doi.org/10.1002/cam4.1505 |
Ejemplares similares
-
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
por: Pataer, Apar, et al.
Publicado: (2022) -
RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer
por: Guo, Chengcheng, et al.
Publicado: (2015) -
Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
por: Parra, Edwin R., et al.
Publicado: (2018) -
The Role of PKR/eIF2α Signaling Pathway in Prognosis of Non-Small Cell Lung Cancer
por: He, Yong, et al.
Publicado: (2011) -
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells
por: Pataer, Apar, et al.
Publicado: (2019)